Fujisawa to market newly-cleared Adenoscan
This article was originally published in Clinica
Medco Research (US) has received US FDA marketing approval for its Adenoscan coronary vasodilator for use in nuclear perfusion imaging. The agent, for coronary artery disease assessment in patients unable to undergo exercise stress testing, will be manufactured and marketed in North America by Fujisawa USA. The two companies have settled their respective lawsuits following a two-year legal battle in which Medco alleged that Fujisawa delayed Adenoscan's launch (see Clinica No 592, p 21). Details of the settlement were not disclosed.
You may also be interested in...
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.